Gilead says it will voluntarily extend 340B pricing to critical access hospitals, sole community hospitals, and rural referral centers on Veklury (remdesivir), its injectable antiviral treatment for COVID-19.

In a Relief to Rural Providers, Gilead Is Waiving 340B Orphan Drug Exclusion for its COVID-19 Drug Veklury

Drug manufacturer Gilead will voluntarily extend 340B pricing to critical access hospitals, sole community hospitals, and rural referral centers on Veklury (remdesivir), its injectable antiviral treatment for COVID-19, the company said late Tuesday.

The U.S. Food and Drug Administration (FDA) late last week approved Veklury for administration to outpatients with mild-to-moderate COVID-19. It previously was approved for inpatient administration only. 340B discounts apply to covered outpatient drugs only. The FDA’s decision meant that 340B pricing became available for the first time on Veklury, which is in very high demand now due to shortages of other therapies.

Drug manufacturer Gilead will voluntarily extend 340B pricing to critical access hospitals, sole community hospitals, and rural referral centers on Veklury (remdesivir), its injectable antiviral treatment for COVID-19, the company said late Tuesday.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report